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Abstract
Background: S100B protein is a potential biomarker of central nervous system insult. This study
quantitatively compared two methods for assessing serum concentration of S100B.
Methods:  A prospective, observational study performed in a single tertiary medical center.
Included were fifty two consecutive adult patients undergoing surgery for meningioma that
provided blood samples for determination of S100B concentrations. Eighty samples (40 pre-
operative and 40 postoperative) were randomly selected for batch testing. Each sample was divided
into two aliquots. These were analyzed by ELISA (Sangtec) and a commercial kit (Roche Elecsys®)
for S100B concentrations. Statistical analysis included regression modelling and Bland-Altman
analysis.
Results: A parsimonious linear model best described the prediction of commercial kit values by
those determined by ELISA (y = 0.045 + 0.277*x, x = ELISA value, R2 = 0.732). ELISA measurements
tended to be higher than commercial kit measurements. This discrepancy increased linearly with
increasing S100B concentrations. At concentrations above 0.7 μg/L the paired measurements were
consistently outside the limits of agreement in the Bland-Altman display. Similar to other studies
that used alternative measurement methods, sex and age related differences in serum S100B levels
were not detected using the Elecsys® (p = 0.643 and 0.728 respectively).
Conclusion: Although a generally linear relationship exists between serum S100B concentrations
measured by ELISA and a commercially available kit, ELISA values tended to be higher than
commercial kit measurements particularly at concentrations over 0.7 μg/L, which are suggestive of
brain injury. International standardization of commercial kits is required before the predictive
validity of S100B for brain damage can be effectively assessed in clinical practice.
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Background
Protein S100 is an acidic, disulfide-linked, dimeric, cal-
cium-binding, low molecular weight protein. The beta
subtype of this protein exists in astrocyte cells in relatively
high concentrations. Rises in serum concentrations of
S100B have been shown to relate to clinical evidence of
CNS damage in the three accepted models of brain injury
in humans-trauma [1-3], ischemia [4] and hypoxia [5].
Significantly higher concentrations of S100B have been
demonstrated in brain death [3] and in non survivors
from cardiopulmonary arrest, compared to survivors
[5,6].
The value of using S100B as an indicator of neurological
injury in the clinical setting is limited by the relatively
high cost and lengthy performance time of the enzyme-
linked immunosorbent assay (ELISA) (currently consid-
ered the best method of analysis), poor substantiation of
reference levels, lack of standardization of serum S-100B
testing and the paucity of data regarding the relationship
between measurement methods. Most studies demon-
strating the potential diagnostic value of serum S-100B in
neurological diseases used an ELISA method (Sangtec
Medical) [1,5,7,8]. Recently a kit for rapid quantification
of S-100B in human serum has become available (Roche
Pharmaceuticals, Elecsys®).
The current study was designed to quantitatively compare
the commercially available Elecsys® assay for serum S100B
protein concentrations with the gold standard ELISA
method and to examine whether this test detects sex- and
age-related differences in serum S100B protein concentra-
tions similar to those demonstrated with ELISA by Gaz-
zolo et al. [9] and Nyberg et al. [10] in pediatric
populations.
Methods
Sampling technique
Following institutional review board approval (Hadassah
Hebrew University Medical Center, reference number 14–
19/12/03) as well as individual patient informed consent,
52 consecutive adult patients aged 18–80 who underwent
supratentorial meningioma surgery over a 10 month
period provided pre- and post operative blood samples
for analysis of S100B concentrations.
Blood samples were drawn into sterile, preservative-free
vacuum containers for the evaluation of S100B in the peri-
operative period as described elsewhere [11]. For the pur-
pose of the current study, samples drawn prior to surgery
(after insertion of an intravenous cannula upon admis-
sion) and immediately after surgery were used. These sam-
pling times were selected based on the assumption that
the broadest range of serum concentrations would be
obtained between the baseline measurement and the
measurement at maximal proximity to surgical insult to
the central nervous system. Previous data have demon-
strated that at this time S100B concentrations are highly
correlated with post-craniotomy neurological deteriora-
tion and unfavorable 6-month outcome [12]. Since the
ELISA array allows batch testing of forty samples at a time,
eighty samples were selected at random for the current
study, 40 pre-operative and 40 postoperative.
Laboratory testing and workup of blood samples
Blood samples were first allowed to clot for 30 min at
room temperature and then centrifuged. Following cen-
trifugation for 15 minutes at 2000 rpm, serum samples
were stored at -70°c for up to ~3 months for batch analy-
sis. The serum samples were then thawed to room temper-
ature, divided into two aliquots and analyzed in parallel
by the ELISA and Elecsys® methods. Diluted serum was
used for higher values in both assays.
Assessment by ELISA
Testing was performed using the Sangtec 100 ELISA
immunosorbent assay for quantitative measurement of
S100B protein in human serum (DiaSorin Inc., Stillwater,
Minnesota, USA). Each sample was incubated together
with an appropriate marker. Washout was performed with
a buffer and tetramethylbenzidine was added as a sub-
strate. Following further incubation a tetramethylbenzi-
dine-arresting substance was added. Spectrophotometric
reading of light absorbance at 450 nm was performed.
Calculation of the result was performed using a cubic
spline algorithm. The calculation range is accurate to a
measured concentration of 5 μg//L.
Assessment by Elecsys®
Testing was performed using the Roche Elecsys® S100 rea-
gent kit (assay duration 18 minutes, measuring range
0.005–39 μg/L, cross reactivity against S100α < 1%). Less
than 24 hr prior to testing calibration was performed per
reagent kit and control values were determined to be
within the limits required for calibration (0.206 μg/L and
2.54 μg/L). The test kit is based on the sandwich principle;
the 1st incubation is performed with a biotinylated mono-
clonal S100-specific antibody and a monoclonal S100-
specific antibody labeled with a ruthenium complex react
to form a sandwich complex. The 2nd incubation: After
addition of streptavidin-coated microparticles the com-
plex becomes bound to the solid phase via interaction of
biotin and streptavidin. The reaction mixture is aspirated
into the measuring cell where the microparticles are mag-
netically captured onto the surface of the electrode.
Unbound substances are then removed with ProCell.
Application of a voltage to the electrode then induces
chemiluminescent emission which is measured by a pho-
tomultiplier. Results are determined via a calibration
curve which is instrument-specifically generated by 2-BMC Clinical Pathology 2008, 8:9 http://www.biomedcentral.com/1472-6890/8/9
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point calibration and a master curve provided via the rea-
gent barcode.
The two laboratory analyses were performed by different
technicians in different times. Both were blinded to the
results of the alternative method.
Statistical analysis
In the first stage, several regression models were used to
examine the Elecsys® method as a function of the ELISA
method using all the samples. These included linear,
quadratic, cubic, logarithmic, inverse, compound, power,
s and growth. Among those models with the best fit
(judged by the R2 value) the most parsimonious was cho-
sen. In the second stage, Bland-Altman analyses [13] were
used to compare the quantification of S100 between Elec-
sys® and ELISA and to detect the existence of systematic
errors. The statistical analyses were performed using SPSS
12 software (SPSS Inc, Chicago, IL). The study endpoint
was examination of the relationship between the two test
methods.
Preoperative samples were used for detection of age- and
sex-related changes in serum S-100B levels using the Elec-
sys® assay. Statistical analyses included the Mann-Whitney
test for comparison between sexes, the Spearman correla-
tion coefficient to evaluate correlation between serum
S100B and age and post-hoc ANOVA to test for differences
between serum S100B levels and age groups.
Results
Quantitative comparison between the two methods
The best fitting models that assessed Elecsys® values as a
function of ELISA values were linear, quadratic and cubic
regressions, with R2values of 0.732, 0.752 and 0.753
respectively. As the R2 values were very similar, the more
parsimonious (in terms of the number of parameters in
the model) linear model was selected to represent the rela-
tionship between the two test methods. The formula for
the regression line of the relationship between the two test
methods was y = 0.045269 + 0.276976*x, with x = ELISA
value (Figure 1).
The mean difference in measurement between the two
tests (ELISA minus Elecsys®) was 0.214 ± 0.277 μg/L.
However, this value is determined by the distribution of
the measured concentrations (i.e. the patient mix) with
the discrepancy being a linear function of the S100B con-
centration. The Bland-Altman analysis clearly demon-
strated that the values determined by ELISA were higher
than by Elecsys®, with the discrepancy increasing in linear
mode as the S100B concentration increased so that the
ELISA values markedly exceeded the Elecsys® values at the
higher concentrations (Figure 2). The degree of discrep-
ancy was very large (>2 SD) at values above 0.7 μg/L (i.e.
in the region of values suggestive of brain injury).
S100B measured using ELISA and Elecsys®, with regression  line Figure 1
S100B measured using ELISA and Elecsys®, with 
regression line. The formula for the regression line of the 
relationship between the two test methods was y = 0.045269 
+ 0.276976*x, with x = ELISA value. All serum concentra-
tions are given in μg/L.
Bland and Altman comparison of serum S100 concentrations  as measured by ELISA and Elecsys® measurements Figure 2
Bland and Altman comparison of serum S100 con-
centrations as measured by ELISA and Elecsys® 
measurements. The x-axis represents the average meas-
urement and the y-axis represents the difference (in μg/L) in 
measurements when these were made using ELISA and Elec-
sys® methods. The mean difference ± 2 SDs are represented 
by horizontal complete and dotted lines respectively. The 
value of the R2 for the regression line is 0.88.BMC Clinical Pathology 2008, 8:9 http://www.biomedcentral.com/1472-6890/8/9
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Relationship between S100B and age
No statistically significant sex difference was noted in
serum S100B concentrations measured by the Elecsys®
method (p = 0.643), nor was there a correlation between
S100B concentration and age (p = 0.728) (figure 3).
Discussion
The current study provides a quantitative comparison of
two tests for measuring the serum concentration of
S100B; ELISA and the commercially available Elecsys®. In
terms of R2 and the number of parameters in the model,
the linear model provided the best fit for the relationship
between the results achieved by these tests. However, in
our hands ELISA measurements were higher than Elecsys®
measurements and particularly so at the higher values,
where the differences in the measurements made using
the two methods were consistently outside the limits of
agreement (2 SDs) as seen in the Bland-Altman display.
Mussack et al. [14] performed a similar analysis in a group
of patients undergoing carotid revascularization. With the
exception of two patients with ongoing damage, the
results of ELISA testing in their series were curtailed at 0.4
μg/L whereas the current paper describes ranges up to 1.2
μg/L. In contrast with our study, Mussack et al. found
small, inconsistent mean differences between the meth-
ods and little or no change in the difference between
methods with increasing S100 concentrations. It is pre-
cisely the divergence at higher values reported in our
paper (i.e. those more likely to be associated with brain
damage) that may cause misclassification of patient status
and prognosis; hence the need for standardization. The
current paper relates to brain damage as a result of an
intracranial operative procedure and may therefore be
more pertinent to the range of test values to be expected
in direct injury to the brain.
Sex and age related differences in serum S100B levels were
not detected using the Elecsys®. This result is consistent
with other studies that used alternative measurement
methods which demonstrated no sex and age differences
in normal adult populations [10,15,16], contrary to pedi-
atric populations [9,10].
There are several subunits of S100 proteins [17], many of
which are expressed selectively by specific cell types. The B
subunit of the S100 protein (S100B) is found in particu-
larly high concentrations in astroglial cells of the central
nervous system and is therefore often referred to as Astro-
cyte Derived Growth Factor [18,19]. S100B is implicated
in the coordinated development and maintenance of the
central nervous system; it stimulates differentiation of
immature neurons [18-23], promotes cell survival
[23,24], induces neurite extension [25] and enhances glial
cell proliferation. Observations of higher S100B concen-
trations humans in infants and adolescence have led some
researchers to suggest that the release of this neurotrophic
factor decreases as the brain matures [9,10].
Serum S100B concentrations rise in clinical situations rep-
resenting the three models of human brain injury –
trauma [1-3], ischemia [4,26] and hypoxia [5,27]. The
degree of elevation is probably related to the severity of
blood-brain barrier disruption [28,29]. Although S100B is
eliminated by the kidneys, in-vivo studies have not shown
a detectable rise in S100B concentration in renal failure,
probably due to its estimated 2 hour biological half life
[30]. Prolonged post-insult elevation of serum S100B con-
centrations therefore most probably reflects ongoing cen-
tral nervous system damage.
Routine use of S100B for early diagnosis of brain injury
remains limited for a number of reasons. Lack of specifi-
city for the biologically active dimeric form of the S-100B
molecule using the actually available assays is a major
problem. This protein can be released from extracerebral
tissue, particularly after surgery [31], potentially con-
founding the association with brain injury and resulting
in misclassification. S100B can be released from the heart
or mediastinum [32,33] and exists in adipose tissue
[34,35], skin, testes [34], skeletal muscle [36] and placen-
tal tissue [37,38], albeit in significantly lower concentra-
tions than in brain tissue. The definition of "normal"
values in humans has yet to be established in each assay
and cutoff values for diagnosis and quantification of the
Relationship of S100B levels with age Figure 3
Relationship of S100B levels with age. Error bar for 
preoperative serum S100B levels (μg/L) by decade for 
patients with meningioma (n = 40). Data are presented 
together for male and female patients since no sex differ-
ences were found.BMC Clinical Pathology 2008, 8:9 http://www.biomedcentral.com/1472-6890/8/9
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presence and extent of brain injury remain undefined.
Clinical applicability is also limited by the lack of stand-
ardization. Different laboratories using the same kit pro-
duced substantially different values [5,6,39,40] and
between-kit variance may be even larger.
Elecsys® analysis requires an electrochemiluminescence
measuring cell. Apart from the initial centrifuging, testing
is fully automated; thus only a few minutes of laboratory
staff time are needed for analysis. The reagent kit suffices
for up to 100 tests. Calibration is required once monthly
and requires two calibration standards in duplicate (4
tests). Two control tests are required daily (2 tests). The
real cost of any test is subject to kit yield which depends
on several variables (e.g. daily number of tests, calibration
and quality control procedures). Calculated yield may be
therefore be greatly affected by internal laboratory regula-
tions. Kit yield is close to maximal at 20 tests per day, at
which point additional costs are almost negligible (Table
1). In 2008 the local price for an Elecsys S100 kit was
1528 . Thus, the theoretical price per test was 15.28 . For
a daily routine of 5 reported results (kit yield 0.6451) the
real price per test was 23.69  and for a daily routine of 12
reported results (kit yield 0.8235) the real price per test
was 18.55 . Additional costs of calibrator and control
materials should be noted: The estimated consumption of
S100 calibrator (price 80.00 /pack) and control (price
189.00 /pack) is 2 and 3 packs/year accordingly, yielding
additional estimated costs of 727 /year. Analysis of
S100B levels by ELISA requires specialized equipment, a
substantial amount of laboratory technician time
(approximately 90 minutes per test) and the test kit
(which costs 1257 ) usually allows for performance of 40
tests. ELISA measurement remains the gold standard for
S100B measurements. However, widespread use of ELISA
remains limited by cost/benefit considerations, mainly
due to its time-consuming nature.
This study provides an assessment of the relationship
between two currently used laboratory methods but does
not address the diagnostic accuracy of either (i.e. sensitiv-
ity or specificity, optimal cutoff points). The inequality
demonstrated between the tests at higher S100 values may
have important implications for its use both as a prognos-
tic marker and for clinical diagnosis as different cutoff
points may be needed for the different test kits – an
overtly undesirable clinical situation. Coefficients of vari-
ation are not given for the measurement methods. One
should also exercise caution in extrapolating the findings
of this study to concentrations of S100B higher than those
included in the study.
Clinical tools for early diagnosis of brain damage in criti-
cally ill patients are lacking. Physical examination and intu-
itive prediction are often the mainstays for both diagnostic
and treatment decisions in these patients. This is a far from
optimal situation in the intensive care environment where
judicious allocation of hospital resources is required; sur-
vival with overwhelming residual neurological disability
and absent or poor quality of life following insult to the
central nervous system incurs expensive in- and out-of-hos-
pital therapy and high indirect costs [40-45].
Table 1: Elecsys® rack-pack yield for 28 days. 
n tests
For clinical use daily For clinical use monthly For calibration For Quality Control Total Kit yield
1 28 16 56 101 0.28
2 56 16 56 130 0.43
3 84 16 56 159 0.53
4 112 16 56 188 0.60
5 140 16 56 217 0.65
10 280 16 56 362 0.77
15 420 4 56 495 0.85
20 560 4 56 640 0.88
25 700 4 56 785 0.89
30 840 4 56 930 0.90
40 1120 4 56 1220 0.92
50 1400 4 56 1510 0.93
60 1680 4 56 1800 0.93
70 1960 4 56 2090 0.94
80 2240 4 56 2380 0.94
90 2520 4 56 2670 0.94
100 2800 4 56 2960 0.95
Data are correct provided manufacturer specifications and recommendations are followed. Kit yield is close to maximal at 20 tests per day, at 
which point additional costs are close to negligible.BMC Clinical Pathology 2008, 8:9 http://www.biomedcentral.com/1472-6890/8/9
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Despite its limitations, serum S100B, one of the most
studied biomarkers of brain damage in the clinical setting,
is currently the only one of which we are aware that holds
promise as an early marker of brain damage and a predic-
tor of probability of survival and severe neurological disa-
bility. Our study points to some shortcomings of currently
available measurement methods and to the need for bet-
ter definition of reference values and for international
standardization of commercial kits so that the predictive
validity of S100B can be effectively assessed in clinical
practice.
Conclusion
Although a general linear relationship exists between
serum S100B concentrations measured by ELISA and a
commercially available kit, ELISA measurements tended
to be higher than commercial kit measurements particu-
larly in concentrations over 0.7 μg/L, which are suggestive
of brain injury. International standardization between
methods of S100B measurements is required to enable
effective assessment of the predictive validity of S100B in
clinical practice.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
SE, YS and JDK are responsible for conceiving and design-
ing the study. EI acquired the data. SE performed data
analysis under expert statistical supervision and drafted
the paper. JDK assisted in interpretation of the data and
provided critical revision of the article together with HO
and CFW.
Acknowledgements
This study was supported by a grant from the Chief Scientist of the Ministry 
of Health, Jerusalem, Israel. Grant number: 5397.
Our gratitude is also given to Dr. Mario Baras who provided expert statis-
tical consult for this paper.
References
1. Pelinka LE, Toegel E, Mauritz W, Redl H: Serum S100β: A marker
of brain damage in traumatic brain injury with and without
multiple trauma.  Shock 2003, 19:195-200.
2. Berger RP, Pierce MC, Wisniewski SR, Adelson PD, Kochanek PM:
Serum S100β concentrations are increased after closed head
injury in children: A preliminary study.  J Neurotrauma 2002,
19:1405-1409.
3. Dimopoulou I, Korfias S, Dafni U, Anthi A, Psachoulia C, Jullien G,
Sakas DE, Roussos C: Protein S-100b serum levels in trauma-
induced brain death.  Neurology 2003, 60:947-951.
4. Foerch C, Singer OC, Neumann-Haefelin T, du Mesnil de Rochemont
R, Steinmetz H, Sitzer M: Evaluation of serum S100B as a surro-
gate marker for long-term outcome and infarct volume in
acute middle cerebral artery infarction.  Arch Neurol 2005,
62:1130-1134.
5. Bottiger BW, Mobes S, Glatzer R, Bauer H, Gries A, Bärtsch P, Mot-
sch J, Martin E: Astroglial protein S-100 is an early and sensitive
marker of hypoxic brain damage and outcome after cardiac
arrest in humans.  Circulation 2001, 103:2694-2698.
6. Rosen H, Rosenberg L, Herlitz J, Blomstrand C: Increased serum
levels of the S-100 protein are associated with hypoxic brain
damage after cardiac arrest.  Stroke 1998, 29:473-477.
7. Weiss N, Sanchez-Peña P, Roche S, Beaudeux JL, Colonne C, Coriat
P, Puybasset L: Prognosis value of plasma S100B protein levels
after subarachnoid aneurysmal hemorrhage.  Anesthesiolog
2006, 104:658-666.
8. Heizmann CW: S100B protein in clinical diagnostics: assay spe-
cificity.  Clin Chem 2004, 50:249-251.
9. Gazzolo D, Michetti F, Bruschettini M, Marchese N, Lituania M, Man-
graviti S, Pedrazzi E, Bruschettini P: Pediatric concentrations of
S100B protein in blood: age- and sex-related changes.  Clin
Chem 2003, 49:967-970.
10. Nygaard O, Langbakk B, Romner B: Age- and sex-related changes
of S-100 protein concentrations in cerebrospinal fluid and
serum in patients with no previous history of neurological
disorder.  Clin Chem 1997, 43:541-543.
11. Einav S, Shoshan Y, Ovadia H, Matot I, Hersch M, Itshayek E: Postop-
erative serum S100B levels predict postoperative brain dam-
age in patients undergoing meningioma surgery.  Crit Care
2006, 10:R141.
12. Stranjalis G, Korfias S, Psachoulia C, Boviatsis E, Kouyialis A, Proto-
pappa D, Sakas DE: Serum S-100B as an indicator of early post-
operative deterioration after meningioma surgery.  Clin Chem
2005, 51:202-207.
13. Bland JM, Altman DG: Statistical methods for assessing agree-
ment between two methods of clinical measurement.  Lancet
1986, 1:307-310.
14. Mussack T, Klauss V, Ruppert V, Gippner-Steppert C, Biberthaler P,
Schiemann U, Hoffmann U, Jochum M: Rapid measurement of S-
100B serum protein levels by Elecsys S100 immunoassay in
patients undergoing carotid artery stenting or endarterec-
tomy.  Clin Biochem 2006, 39:349-356.
15. Wiesmann M, Missler U, Gottmann D, Gehring S: Plasma S-100b
protein concentration in healthy adults is age- and sex-inde-
pendent.  Clin Chem 1998, 44:1056-1057.
16. Portela LV, Tort AB, Schaf DV, Ribeiro L, Nora DB, Walz R, Rotta
LN, Silva CT, Busnello JV, Kapczinski F, Gonçalves CA, Souza DO:
The serum S100B concentration is age dependent.  Clin Chem
2002, 48:950-952.
17. Barger SW, Van Eldik LJ: S100 beta stimulates calcium fluxes in
glial and neuronal cells.  J Biol Chem 1992, 267:9689-9694.
18. Schäfer BW, Heizmann CW: The S100 family of EF-hand cal-
cium binding proteins: functions and pathology.  Trends Bio-
chem Sci 1996, 21:134-140.
19. Zimmer DB, Cornwall EH, Landar A, Song W: The S100 protein
family: history, function, and expression.  Brain Res Bull 1995,
37:417-429.
20. McAdory BS, Van Eldik LJ, Norden JJ: S100B, a neurotropic pro-
tein that modulates neuronal protein phosphorylation, is
upregulated during lesion induced collateral sprouting and
reactive synaptogenesis.  Brain Res 1998, 813:211-217.
21. Selinfreund RH, Barger SW, Pledger WJ, Van Eldik LJ: Neurotrophic
protein S100 beta stimulates glial cell proliferation.  Proc Natl
Acad Sci USA 1991, 88:3554-3558.
22. Donato R: Functional roles of S100 proteins, calcium-binding
proteins of the EF-hand type.  Biochim Biophys Acta 1999,
1450:191-231.
23. Bhattacharyya A, Oppenheim RW, Prevette D, Moore BW, Bracken-
bury R, Ratner N: S100 is present in developing chicken neu-
rons and Schwann cells and promotes motor neuron survival
in vivo.  J Neurobiol 1992, 23:451-466.
24. Winningham-Major F, Staecker JL, Barger SW, Coats S, Van Eldik LJ:
Neurite extension and neuronal survival activities of recom-
binant S100 beta proteins that differ in the content and posi-
tion of cysteine residues.  J Cell Biol 1989, 109:3063-3071.
25. Kligman D, Marshak DR: Purification and characterization of a
neurite extension factor from bovine brain.  Proc Natl Acad Sci
USA 1985, 82:7136-7139.
26. Mussack T, Hauser C, Klauss V, Tató F, Rieger J, Ruppert V, Jochum
M, Hoffmann U: Serum S-100B protein levels during and after
successful carotid artery stenting or carotid endarterec-
tomy.  J Endovasc Ther 2006, 13:39-46.
27. Rosen H, Rosenberg L, Herlitz J, Blomstrand C: Increased serum
levels of the S-100 protein are associated with hypoxic brain
damage after cardiac arrest.  Stroke 1998, 29:473-477.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Clinical Pathology 2008, 8:9 http://www.biomedcentral.com/1472-6890/8/9
Page 7 of 7
(page number not for citation purposes)
28. Kanner AA, Marchi N, Fazio V, Mayberg MR, Koltz MT, Siomin V, Ste-
vens GH, Masaryk T, Aumayr B, Vogelbaum MA, Barnett GH, Janigro
D:  Serum S100beta: a noninvasive marker of blood-brain
barrier function and brain lesions.  Cancer 2003, 97:2806-2813.
2 9 . M a r c h i  N ,  C a v a g l i a  M ,  F a z i o  V ,  B h u d i a  S ,  H a l l e n e  K ,  J a n i g r o  D :
Peripheral markers of blood-brain barrier damage.  Clin Chim
Acta 2004, 342:1-12.
30. Ytrebo LM, Nedredal GI, Korvald C, Holm Nielsen OJ, Ingebrigtsen
T, Romner B, Aarbakke J, Revhaug A: Renal elimination of protein
S-100beta in pigs with acute encephalopathy.  Scand J Clin Lab
Invest 2001, 61:217-225.
31. Fazio V, Bhudia SK, Marchi N, Aumayr B, Janigro D: Peripheral
detection of S100beta during cardiothoracic surgery: what
are we really measuring?  Ann Thorac Surg 2004, 78:46-53.
32. Snyder-Ramos SA, Gruhlke T, Bauer H, Bauer M, Luntz AP, Motsch J,
Martin E, Vahl CF, Missler U, Wiesmann M, Böttiger BW: Cerebral
and extracerebral release of protein S100B in cardiac surgi-
cal patients.  Anaesthesia 2004, 59:344-349.
33. Anderson RE, Hansson LO, Nilsson O, Liska J, Settergren G, Vaage J:
Increase in serum S100A1-B and S100BB during cardiac sur-
gery arises from extracerebral sources.  Ann Thor Surg 2001,
71:1512-1517.
34. Zimmer DB, Van Eldik LJ: Tissue distribution of rat S100 alpha
and S100 beta and S100-binding proteins.  Am J Physiol 1987,
252:C285-289.
35. Suzuki F, Kato K, Nakajima T: Hormonal regulation of adipose S-
100 protein release.  J Neurochem 1984, 43:1336-1341.
36. Arcuri C, Giambanco I, Bianchi R, Donato R: Annexin V, annexin
VI, S100A1 and S100B in developing and adult avian skeletal
muscles.  Neuroscience 2002, 109:371-388.
37. Gazzolo D, Marinoni E, Di Iorio R, Lituania M, Bruschettini PL,
Michetti F: Circulating S100B protein is increased in intrauter-
ine growth retarded fetuses.  Pediatr Res 2002, 51:215-219.
38. Wijnberger LD, Nikkels PG, van Dongen AJ, Noorlander CW, Mulder
EJ, Schrama LH, Visser GH: Expression in the placenta of neuro-
nal markers for perinatal brain damage.  Pediatr Res 2002,
51:492-496.
39. Martens P, Raabe A, Johnsson P: Serum S-100 and neuron-spe-
cific enolase for prediction of regaining consciousness after
global cerebral ischemia.  Stroke 1998, 29:2363-2366.
40. Hachimi-Idrissi S, Auwera M Van der, Schiettecatte J, Ebinger G,
Michotte Y, Huyghens L: S-100 protein as early predictor of
regaining consciousness after out of hospital cardiac arrest.
Resuscitation 2002, 53:251-257.
41. Lee KH, Angus DC, Abramson NS: Cardiopulmonary resuscita-
tion: What cost to cheat death?  Crit Care Med 1996,
24:2046-2052.
42. Tilford JM, Aitken ME, Anand KJ, Green JW, Goodman AC, Parker JG,
Killingsworth JB, Fiser DH, Adelson PD: Hospitalizations for crit-
ically ill children with traumatic brain injuries: a longitudinal
analysis.  Crit Care Med 2005, 33:2074-2081.
43. Vangel SJ Jr, Rapport LJ, Hanks RA, Black KL: Long-term medical
care utilization and costs among traumatic brain injury sur-
vivors.  Am J Phys Med Rehabil 2005, 84:153-160.
44. Claesson L, Gosman-Hedstrom G, Johannesson M, Fagerberg B,
Blomstrand C: Resource utilization and costs of stroke unit
care integrated in a care continuum: A 1-year controlled,
prospective, randomized study in elderly patients: the Gote-
borg 70+ Stroke Study.  Stroke 2000, 31:2569-2577.
45. Porsdal V, Boysen G: Costs of health care and social services
during the first year after ischemic stroke.  Int J Technol Assess
Health Care 1999, 15:573-584.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1472-6890/8/9/prepub